The case for & against
Bull & Bear analysis
Bullish
Novartis AG (NYSE: NVS) is a leading global healthcare company that specializes in patented pharmaceuticals across various therapeutic areas, including oncology, cardiology, and immunology. With a robust pipeline and a commitment to innovative therapies, Novartis is positioned to tackle significant healthcare needs. The company's recent focus on acquiring Avidity Biosciences aligns with its strategy to strengthen its presence in neuromuscular diseases, utilizing advanced RNA technologies to address high unmet clinical needs.
Bull says
- ↑Q4 2025 sales at $48.7B, up 8% YoY; core operating income rose 14% to $21.9B, supporting a 40.1% margin.
- ↑Free cash flow reached $17.6B (+8% YoY), funding a $10B share buyback and 3.70 CHF dividend (29th year of growth).
- ↑Kiskali (+57% sales) and Fluvicto (+42%) drove Q1 2026 growth, reflecting strong execution in oncology portfolio.
- ↑Avidity Biosciences acquisition expands neuromuscular pipeline, targeting multi-billion-dollar markets with advanced RNA therapies.
- ↑High dividend yield and robust profitability metrics underline sustainable shareholder returns amid R&D investments.
- ↑Positive share momentum and manageable leverage enhance resilience against market volatility.
Bear says
- ↓Pelacarsen and del-desiran trial failures drove stock volatility and undermined growth outlook.
- ↓Impending generic Entresto entry threatens significant revenue erosion in core markets.
- ↓High short interest underscores investor skepticism toward turnaround prospects.
- ↓Rising R&D expenses and regulatory reforms strain margins and could slow earnings.
- ↓Liquidity and revision pressures may limit strategic investments and cash flexibility.
- ↓Governance concerns and strategy scrutiny add uncertainty to long-term execution.
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 09-13-2026bullish
Transcript signals
Bull points
- net sales grew plus 11% in quarter two year-over-year and core operating income grew 21%
- Our core margin was 42.2%, reflecting a 340 basis point improvement. Core EPS was $2.42, up 24%
- Cash flow was even $6.3 billion, up 37% in US dollars
Bear points
- We continue to expect high single-digit sales growth; however, the dynamics in quarter three and quarter four would be quite different with anticipated step downs in growth reflecting a potential full quarter impact of generic entries for Entresto in the U.S.
Read full transcript analysis ›